Dunhill Financial’s NovoCure NVCR Stock Holding History

Dunhill Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23	Hold	2	–	–	﹤0.01%	1750
2025 Q4	$28	Buy	+2	New	+$26	﹤0.01%	1839

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Dunhill Financial's NVCR Position: Q1 2026 in Review

Dunhill Financial held its NovoCure (NVCR) position steady in Q1 2026 at 2 shares worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Dunhill Financial first reported a position in NVCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $28 in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Dunhill Financial held 2 shares of NovoCure worth $23 as of Q1 2026.
Dunhill Financial left its NovoCure share count unchanged in Q1 2026.
NovoCure made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #1750 holding.
Dunhill Financial first reported a position in NovoCure in Q4 2025 and has held it in 2 quarters since.
Dunhill Financial's NovoCure position peaked at $28 in Q4 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.